Oncocyte Stock Forecast, Price & News Nyseamerican

In the past three months, OncoCyte insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $152,400.00 in company stock and sold $0.00 in company stock. OncoCyte has only been the subject of 3 research reports in the past 90 days. Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat’s FREE daily newsletter. Advanced charts with more than 100 technical indicators, tools and studies will give you the edge, making it easier to negotiate the market and its swings. Mutual Funds have increased holdings from 3.73% to 4.02% in Dec 2021 qtr.

OCX is currently trading in the 30-40% percentile range relative to its historical Stock Score levels. Over the past 69 months, OCX’s EV/EBIT ratio has gone up 24.3. OCX’s EV/EBIT ratio is -9; this is 130.72% lower than that of the median Healthcare stock. Visit OCX’s SEC page to see the company’s official filings. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

To cancel a subscription, please send an email to stating your request to cancel before your next rebill date. Upon cancelling a subscription there are no pro-rated refunds. I understand my credit card will be charged $7 today for 7 days of Platinum access.

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for checking the competitive advantage potential of cross-business strategic fit involves detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

At the end of my 7 days, my credit card will be conveniently charged $397/quarterly until I cancel. To see all exchange delays and terms of use, please see disclaimer. Below are the latest news stories about Oncocyte Corp that investors may wish to consider to help them evaluate OCX as an investment opportunity.

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. OncoCyte has a market capitalization of $123.15 million and generates $7.73 million in revenue each year. The biotechnology company earns $-64.10 million in net income each year or ($0.71) on an earnings per share basis.

To buy shares in Oceanethix International Holdings you’ll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you’ll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

Contact your intermediary and elect for the RETENTION option. Below you will find the price predictions for 2022, 2023, 2024, 2025, 2026, 2027. One share of OCX stock can currently be purchased for approximately $1.34.

TipRanks is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who provides financial advice. Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis. Fractional shares are pieces of one full share of a company or exchange-traded fund . OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on the development of a non-invasive confirmatory blood test for lung cancer called DetermaDx. The DetermaDx is the test to predict a post-surgery patient’s risk of cancer recurrence and their response to chemotherapy in early-stage lung cancer. Its development pipeline includes TheraSure CNI Monitor, which is a blood-based test for immunotherapy monitoring, and TheraSure Transplant Monitor, a solid organ transplantation monitoring test. Its other DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq and Imfinzi.

In the news